WJPPS Citation

Login

Search

News & Updation

  • Updated Version
  • WJPPS introducing updated version of OSTS (online submission and tracking system), which have dedicated control panel for both author and reviewer. Using this control panel author can submit manuscript
  • Call for Paper
    • WJPPS  Invited to submit your valuable manuscripts for Coming Issue.
  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.
  •  
  • New Impact Factor
  • WJPPS Impact Factor has been Increased to 8.025 for Year 2024.

  • WJPPS: MARCH ISSUE PUBLISHED
  • March Issue has been successfully launched on 1 March 2024.

  • ICV
  • WJPPS Rank with Index Copernicus Value 84.65 due to high reputation at International Level

  • Scope Indexed
  • WJPPS is indexed in Scope Database based on the recommendation of the Content Selection Committee (CSC).

Abstract

ASSESSMENT OF ENDOTHELIN RECEPTOR ANTAGONIST IN REDUCING DIABETIC COMPLICATIONS

Gaju Sowmya Sri* and Dr. Challa Pradeep Kumar

ABSTRACT

Back ground: Diabetes mellitus and its complications are common problem in now a days. So many people suffering with diabetes complications and no satisfactory method available for complete cure. Hydralazine it is commonly used in hypertension and endothelin receptor antagonist hydralazine to have wide range of pharmacological applications. Object: The present study was aimed at evaluating the anti diabetic activity & diabetic nephropathy, diabetic cardiomyopathy of endothelin receptor antagonist (Hydralazine) against alloxan induced diabetic rats. Method: Rats were randomly divided into four groups with four animals in each group based on respective weights. Group-1 rats served as normal control. Group-2 served as diabetic control was treated with single dose of alloxan monohydrate (150mg/kg i.p). Group-3 served as standard group and was treated with glimipride at dose of 10mg/kg. Group-4 served as test group which were treated with hydralazine (10mg/kg) respectively for 28days. After single dose of alloxan( 150mg/kg i.p) on 3rd and 28th day blood samples were collected from all animals and levels of glucose, uric acid, creatinine, troponin I levels were examined in serum, heart and kidney tissues of control and experimental groups were examined by histopathology. Result: By the oral administration of hydralazine were resulted in the significant reduction value of troponine-1, creatinine, uric acid, blood glucose level in diabetic rats and no significant changes in these parameters were observed in the control group. The effect produced by the test (hydralazine) drug was closely similar to that of standard anti diabetic drug, glimipride. Conclusion: In conclusion, the present study indicates the ET-receptor antagonist hydralazine may have some protective effect against alloxan induced diabetic cardiomyopathy and nephropathy.

Keywords: Endothelin, Hydralazine, Troponin-1, Creatinine, Uric Acid.


[Download Article]     [Download Certifiate]

Call for Paper

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More

Online Submission

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More

Email & SMS Alert

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More